The Monarch School

Lilly Announces Details of Presentations at ESMO Congress 2023

Retrieved on: 
Friday, October 6, 2023
Congress, Selpercatinib, Eli Lilly and Company, ID, NYSE, NSCLC, RET, Risk, Adjuvant, MTC, Lilly, The Monarch School, Triple-negative breast cancer, Recurrence, Everolimus, CEST, Oncology, ESMO, LLY, EMBER, EBC, Transfection, ET, Vandetanib, European Society for Medical Oncology, Patient, Poster, Cabozantinib, Pharmaceutical industry, Vaccine

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Key Points: 
  • In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.
  • A separate poster presentation will provide data on the impact of dose reductions on efficacy for patients treated in monarchE.
  • In two late-breaking oral presentations that will be featured as part of the Presidential Symposium 1 on Saturday, October 21, Lilly will share interim analysis results from the Phase 3 LIBRETTO-431 and LIBRETTO-531 clinical studies.
  • In a mini oral presentation, Lilly will share clinical data on imlunestrant as a single agent and in combination therapy.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
The Monarch School, Adult, Cell death, Food and Drug Administration, PI3K, Growth, Cancer, EMBER, Cyclin D1, Recurrence, Plasma, Breast, Febrile neutropenia, PIK3CA, Rb, Woman, Cell proliferation, Diarrhea, SERD, Infection, ER, Tamoxifen, Traffic barrier, CDK, Physician, Cerebrospinal fluid, Eli Lilly and Company, FDA, Breast cancer, Breast cancer classification, Phosphorylation, ESR1, ET, EBC, NYSE, OS, S phase, Hospital, Pharmacology, Patient, Molecular biology, Grade 3, Apoptosis, Toxicity, Risk, Dehydration, Cyclin-dependent kinase, Loperamide, Lilly, Retinoblastoma protein, Food, Cell cycle, Preclinical development, Grade 2, Pharmaceutical industry, Birth control, Medical imaging, Abemaciclib, Neutropenia, G1

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.

Key Points: 
  • INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.
  • In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

Kayne Anderson Closed-End Funds Announce Appointment of New Independent Director

Retrieved on: 
Wednesday, April 27, 2022
The Monarch School, NYSE, California State University, CEO, Energy transition, Sale, LLC, Energy, Investment, Scripps Institution of Oceanography, Thought, GLOBE, Investment Company Act of 1940, Policy, San Diego Gas & Electric, Forward-looking statement, Company, Fund, SDG&E, Communication, Renewable energy transition, KMF, Board, Knowledge, Industry, SEC, California State University, Sacramento, SDG, Monarch School (San Diego), Financial adviser, Management, Security (finance), Oceanography

HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- KA Fund Advisors, LLC (Kayne Anderson), which serves as the adviser to Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) and Kayne Anderson NextGen Energy & Infrastructure, Inc. (NYSE: KMF, each a Company and collectively, the Companies) announced today the appointment of Caroline Winn to serve as an independent director on each Companys Board of Directors, effective today.

Key Points: 
  • HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- KA Fund Advisors, LLC (Kayne Anderson), which serves as the adviser to Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) and Kayne Anderson NextGen Energy & Infrastructure, Inc. (NYSE: KMF, each a Company and collectively, the Companies) announced today the appointment of Caroline Winn to serve as an independent director on each Companys Board of Directors, effective today.
  • After the addition of Ms. Winn, the board of directors of each Company will increase to seven directors, six of which are independent.
  • Kayne Anderson is thrilled to welcome Caroline to KYN and KMFs Board of Directors, said Jim Baker, KYN and KMFs Chairman, President, and CEO.
  • Kayne Anderson undertakes no obligation to publicly update or revise any forward-looking statements made herein.

Arnold & Itkin LLP Awarding $45,000 in Scholarships at 6 Law Schools

Retrieved on: 
Friday, April 15, 2022
BP, Student, Multimedia, Arnold, Johnson & Johnson, The Monarch School, School, Shell, Pharmaceutical industry, Medicine

HOUSTON, April 15, 2022 /PRNewswire/ -- Arnold & Itkin LLP recently announced that they will be awarding $45,000 in scholarships to 6 law students at schools throughout Texas, Louisiana, and Utah. The scholarships include three (3) $10,000 scholarships and three (3) $5,000 scholarships to be awarded to either 1L or 2L law students.

Key Points: 
  • The Houston trial law firm will be awarding scholarships to six law students from schools in Texas, Louisiana, and Utah.
  • HOUSTON, April 15, 2022 /PRNewswire/ -- Arnold & Itkin LLP recently announced that they will be awarding $45,000 in scholarships to 6 law students at schools throughout Texas, Louisiana, and Utah.
  • The scholarships include three (3) $10,000 scholarships and three (3) $5,000 scholarships to be awarded to either 1L or 2L law students.
  • The scholarships will go to students attending the following schools:
    Arnold & Itkin expressed that the scholarships were a way to "invest into the next cohort of plaintiffs' attorneys."